Partner with Agendia

Bring Personalized Medicine Directly to Your Early Stage Breast Cancer Patients

AGENDIA®

PRECISION ONCOLOGY

The Value MammaPrint® and BluePrint® Brings to Your Patients

Agendia's MammaPrint and BluePrint tests together provide a comprehensive genomic profile to help physicians make more informed decisions in pre- and post-operative treatment settings.

MammaPrint, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines.[1,2,3,4,5] BluePrint, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint and BluePrint help physicians better tailor treatment and the timing of surgery to an individual patient.

Pre-operative Treatment Planning Utility

Prospective clinical trials demonstrate that MammaPrint and BluePrint accurately predict pathological complete response (pCR) and can be used to support neoadjuvant treatment planning.[6,7,8,9]

- The pCR rates for BluePrint subtypes are similar to the pCR rates for pathologic subtypes, confirming the accuracy of molecular subtyping.[6]





- MammaPrint provides a High or Low Risk of recurrence along with a numerical index (MammaPrint Index, MPI) that is negative for High Risk and positive for Low Risk. As the MPI approaches -1, there is a higher probability of pCR to neoadjuvant therapy.[9]

Post-operative Chemotherapy Planning Utility

Key landmark trials, including MINDACT and STO-3, demonstrate that MammaPrint can be used to inform adjuvant chemotherapy and endocrine therapy planning.[5,10]

- MINDACT shows that MammaPrint can be used to de-escalate adjuvant treatment in nearly 50% of clinically high-risk patients, without impacting their outcomes.[5]
- Data from prospective trials demonstrate that patients with an Ultra-Low risk of recurrence (MPI > +0.355) have excellent outcomes with limited or no endocrine therapy.[10,11,12]

BCSS in the Stockholm Tamoxifen Trial (STO-3)



Re-classifying Patients with BluePrint

NBRST: Differential Outcomes in Clinically ER+ Patients Stratified by pCR



One of the primary benefits of BluePrint is identifying discordance between pathologic and molecular subtyping.

- BluePrint consistently reclassifies 16-22% of patients from their pathologic subtype.[6,7,8]
- BluePrint is the only test able to identify ER+/Basal patients, a subset of pathologically hormone receptor positive patients who have very aggressive disease that acts like triple negative breast cancer.[6]

Integrating Genomics into Diagnostic Workup Processes



Consider Increasing Your Laboratory's Precision Oncology Impact with the MammaPrint® NGS Assay*

Currently, MammaPrint is only offered by Agendia's central laboratory. We're developing a decentralized NGS test that will allow US laboratories to have the ability to provide MammaPrint results directly to their clinicians. Through rigorous scientific validation, we have migrated MammaPrint's 70-gene microarray test to the Illumina® MiSeq Dx® NGS platform with the MammaPrint NGS Kit, a targeted RNA sequencing technology.[13] Our proprietary, cloud-based ADAPT results pipeline will conveniently and securely convert your FASq files to MammaPrint risk of recurrence results.

Partnering with Agendia to offer MammaPrint testing will provide key benefits to your laboratory and the clinicians you support, such as:

- Expanding your next generation genomics footprint to personalize treatment planning for early stage breast cancer patients directly to your institution.
- The ability to retain patient tissue, decrease utilization of personnel for send-outs and the potential to provide critical genomic test results more quickly.
- A dedicated category 1 CPT code will facilitate consistent reimbursement from CMS and private payers, increasing the return on investment of your NGS platform.

Contact Us

To learn more contact your Agendia Medical Oncology Specialist or Agendia customer care at customercare@agendia.com or 888.321.2732

* Under development, US FDA 510(k) pending; not available for sale within the United States yet.

References

1) Journal of Clinical Oncology 2017 35:24, 2838-2847
2) National Comprehensive Cancer Network (Version 3.2020)
3) Burstein H. et al, Ann Oncol. 2019;30:1541-1557
4) FDA IVDMIA 510K cleared, 2007
5) Cardoso, F. et al., NEJM 2016;375:717-729
6) Whitworth, et. al, SABCS 2020, PD9-01
7) Groenendijk, F. et al., npj Breast Cancer 2019;5, 15
8) Beitsch,. P., et al. Ann Surg Oncol. 2017;24(9):2539-2546
9) Whitworth, P., et al. Ann Surg Oncol 2017;24: 669–675
10) Esserman L., JAMA Oncol. 2017; 3(11):1503-1510. 823
11) Opdam, M. et al, ESMO Congress 2020, 171P
12) Noordhoek, I., et. al, SABCS 2020, PS6-06
13) Mittempergher L et al., J Mol Diagn. 2019; 21:808-823